BridgeMD
New treatment option for Multiple Myeloma
Official title A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
ClinicalTrials.gov ID: NCT06500884
What this study is testing
What is Talquetamab?
Talquetamab is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for multiple myeloma.
Also referred to as CD3xGPRC5D.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to better characterize the signs or symptoms of ramantamig-related taste changes.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Multiple myeloma (MM) according to IMWG diagnostic criteria
- Were triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb)
- Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen
- Have an Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0 or 1 at screening. Participants with ECOG-PS 2 or 3 are eligible for the...
- Be willing and able to adhere to the lifestyle restrictions specified in the protocol
You likely can't join if
- Contraindications or life-threatening known allergies, hypersensitivity, or intolerance to any study drug or its excipients
- Stroke, transient ischemic attack, or seizure within 6 months prior to screening
- Any of the following within 6 months prior to the first dose of study treatment: severe or unstable angina, myocardial infarction; major...
- Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully...
- A WETT score indicating severe dysgeusia at screening and confirmed prior to randomization. Also unresolved/severe dysgeusia referred by the...
The study team makes the final eligibility decision.
Where it's taking place
- San Francisco, California, United States
- Denver, Colorado, United States
- New Haven, Connecticut, United States
- New York, New York, United States
- Rochester, New York, United States
- Durham, North Carolina, United States
- Cleveland, Ohio, United States
- Richmond, Virginia, United States
- Seattle, Washington, United States
- Brasília, Brazil
- Caxias do Sul, Brazil
- Curitiba, Brazil
- Salvador, Brazil
- São Paulo, Brazil
- Amsterdam, Netherlands
- Dordrecht, Netherlands
- Rotterdam, Netherlands
- San Juan, Puerto Rico
- Seoul, South Korea
- Badalona, Spain
+ 13 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include San Francisco, California, United States; Denver, Colorado, United States; New Haven, Connecticut, United States; New York, New York, United States; Rochester, New York, United States; Durham, North Carolina, United States and 27 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.